

Andrew J Godkin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3310498/publications.pdf>

Version: 2024-02-01

88
papers

5,189
citations

87723

38
h-index

91712

69
g-index

90
all docs

90
docs citations

90
times ranked

8768
citing authors

#	ARTICLE	IF	CITATIONS
1	Induction and Exhaustion of Lymphocytic Choriomeningitis Virus-specific Cytotoxic T Lymphocytes Visualized Using Soluble Tetrameric Major Histocompatibility Complex Class II Peptide Complexes. <i>Journal of Experimental Medicine</i> , 1998, 187, 1383-1393.	4.2	688
2	In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope. <i>Nature Medicine</i> , 2000, 6, 337-342.	15.2	521
3	VDJdb in 2019: database extension, new analysis infrastructure and a T-cell receptor motif compendium. <i>Nucleic Acids Research</i> , 2020, 48, D1057-D1062.	6.5	268
4	CD4+CD25+FOXP3+ Regulatory T Cells Suppress Anti-Tumor Immune Responses in Patients with Colorectal Cancer. <i>PLoS ONE</i> , 2006, 1, e129.	1.1	183
5	Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1271-1286.	2.0	161
6	Interleukin-6 limits influenza-induced inflammation and protects against fatal lung pathology. <i>European Journal of Immunology</i> , 2013, 43, 2613-2625.	1.6	143
7	Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramers. <i>Journal of Immunological Methods</i> , 2009, 340, 11-24.	0.6	134
8	Suppression of tumour-specific CD4 ⁺ T cells by regulatory T cells is associated with progression of human colorectal cancer. <i>Gut</i> , 2012, 61, 1163-1171.	6.1	127
9	Naturally Processed HLA Class II Peptides Reveal Highly Conserved Immunogenic Flanking Region Sequence Preferences That Reflect Antigen Processing Rather Than Peptide-MHC Interactions. <i>Journal of Immunology</i> , 2001, 166, 6720-6727.	0.4	125
10	Molecular analysis of HLA class II associations with hepatitis B virus clearance and vaccine nonresponsiveness. <i>Hepatology</i> , 2005, 41, 1383-1390.	3.6	125
11	COVID-19 Vaccine Response in People with Multiple Sclerosis. <i>Annals of Neurology</i> , 2022, 91, 89-100.	2.8	119
12	Low-Dose Cyclophosphamide Induces Antitumor T-Cell Responses, which Associate with Survival in Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 6771-6780.	3.2	114
13	Analysis of the T-Cell Receptor Repertoires of Tumor-Infiltrating Conventional and Regulatory T Cells Reveals No Evidence for Conversion in Carcinogen-Induced Tumors. <i>Cancer Research</i> , 2011, 71, 736-746.	0.4	112
14	More tricks with tetramers: a practical guide to staining T cells with peptide-MHC multimers. <i>Immunology</i> , 2015, 146, 11-22.	2.0	106
15	Evolution of Epitope-Specific Memory CD4 ⁺ T Cells After Clearance of Hepatitis C Virus. <i>Journal of Immunology</i> , 2002, 169, 2210-2214.	0.4	99
16	T-Cell Trafficking Facilitated by High Endothelial Venules Is Required for Tumor Control after Regulatory T-Cell Depletion. <i>Cancer Research</i> , 2012, 72, 5473-5482.	0.4	97
17	Regulatory T cells and tumour immunity – observations in mice and men. <i>Immunology</i> , 2008, 123, 157-163.	2.0	94
18	The pathogenesis of celiac disease. <i>Gastroenterology</i> , 1998, 115, 206-210.	0.6	91

#	ARTICLE	IF	CITATIONS
19	Interleukin-6 Is Crucial for Recall of Influenza-Specific Memory CD4+ T Cells. <i>PLoS Pathogens</i> , 2008, 4, e1000006.	2.1	89
20	Treg Depletion Licenses T Cell-Driven HEV Neogenesis and Promotes Tumor Destruction. <i>Cancer Immunology Research</i> , 2017, 5, 1005-1015.	1.6	78
21	The Ussing chamber system for measuring intestinal permeability in health and disease. <i>BMC Gastroenterology</i> , 2019, 19, 98.	0.8	72
22	Home Sweet Home: The Tumor Microenvironment as a Haven for Regulatory T Cells. <i>Frontiers in Immunology</i> , 2013, 4, 197.	2.2	70
23	T-cell Receptor (TCR)-Peptide Specificity Overrides Affinity-enhancing TCR-Major Histocompatibility Complex Interactions. <i>Journal of Biological Chemistry</i> , 2014, 289, 628-638.	1.6	63
24	Structural basis for ineffective T-cell responses to MHC anchor residue-improved heteroclitic peptides. <i>European Journal of Immunology</i> , 2015, 45, 584-591.	1.6	63
25	Characterization of novel HLA-DR11-restricted HCV epitopes reveals both qualitative and quantitative differences in HCV-specific CD4+ T cell responses in chronically infected and non-viremic patients. <i>European Journal of Immunology</i> , 2001, 31, 1438-1446.	1.6	60
26	High endothelial venules are rare in colorectal cancers but accumulate in extra-tumoral areas with disease progression. <i>Oncotarget</i> , 2015, 4, e974374.	2.1	60
27	Re-Directing CD4+ T Cell Responses with the Flanking Residues of MHC Class II-Bound Peptides: The Core is Not Enough. <i>Frontiers in Immunology</i> , 2013, 4, 172.	2.2	58
28	Antibody Stabilization of Peptide-MHC Multimers Reveals Functional T Cells Bearing Extremely Low-Affinity TCRs. <i>Journal of Immunology</i> , 2015, 194, 463-474.	0.4	55
29	The paradox of NKp46 ⁺ natural killer cells: drivers of severe hepatitis C virus-induced pathology but in-vivo resistance to interferon β treatment. <i>Gut</i> , 2014, 63, 515-524.	6.1	54
30	T-cell modulation by cyclophosphamide for tumour therapy. <i>Immunology</i> , 2018, 154, 62-68.	2.0	53
31	Regulating the immune response to tumours. <i>Advanced Drug Delivery Reviews</i> , 2006, 58, 948-961.	6.6	51
32	Remarkably low affinity of CD4/peptide-major histocompatibility complex class II protein interactions. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 5682-5687.	3.3	51
33	Effect of Modified Vaccinia Ankara-5T4 and Low-Dose Cyclophosphamide on Antitumor Immunity in Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2017, 3, e172579.	3.4	51
34	Efficacy of rituximab in difficult-to-manage autoimmune hepatitis: Results from the International Autoimmune Hepatitis Group. <i>JHEP Reports</i> , 2019, 1, 437-445.	2.6	48
35	Novel role of regulatory T cells in limiting early neutrophil responses in skin. <i>Immunology</i> , 2010, 131, 583-592.	2.0	47
36	Epithelial Barriers, Microbiota, and Colorectal Cancer. <i>New England Journal of Medicine</i> , 2013, 368, 282-284.	13.9	47

#	ARTICLE	IF	CITATIONS
37	CD59 Blockade Enhances Antigen-Specific CD4+ T Cell Responses in Humans: A New Target for Cancer Immunotherapy?. <i>Journal of Immunology</i> , 2009, 182, 5203-5207.	0.4	46
38	Cytomegalovirus-Specific IL-10-Producing CD4+ T Cells Are Governed by Type-I IFN-Induced IL-27 and Promote Virus Persistence. <i>PLoS Pathogens</i> , 2016, 12, e1006050.	2.1	46
39	Paracetamol reduces influenza-induced immunopathology in a mouse model of infection without compromising virus clearance or the generation of protective immunity. <i>Thorax</i> , 2011, 66, 368-374.	2.7	39
40	Type I Interferon (IFN α) Acts Directly on Human Memory CD4+T Cells Altering Their Response to Antigen. <i>Journal of Immunology</i> , 2009, 183, 2915-2920.	0.4	38
41	Modification of the carboxy-terminal flanking region of a universal influenza epitope alters CD4+ T-cell repertoire selection. <i>Nature Communications</i> , 2012, 3, 665.	5.8	36
42	Anti-CD8 Antibodies Can Trigger CD8+ T Cell Effector Function in the Absence of TCR Engagement and Improve Peptideâ€“MHC I Tetramer Staining. <i>Journal of Immunology</i> , 2011, 187, 654-663.	0.4	34
43	Potent T cell agonism mediated by a very rapid TCR/pMHC interaction. <i>European Journal of Immunology</i> , 2007, 37, 798-806.	1.6	30
44	The Dual Role of High Endothelial Venules in Cancer Progression versus Immunity. <i>Trends in Cancer</i> , 2021, 7, 214-225.	3.8	28
45	Minimal conformational plasticity enables TCR cross-reactivity to different MHC class II heterodimers. <i>Scientific Reports</i> , 2012, 2, 629.	1.6	26
46	In Silico and Structural Analyses Demonstrate That Intrinsic Protein Motions Guide T Cell Receptor Complementarity Determining Region Loop Flexibility. <i>Frontiers in Immunology</i> , 2018, 9, 674.	2.2	26
47	Seven mysteries of LAG-3: a multi-faceted immune receptor of increasing complexity. <i>Immunotherapy Advances</i> , 2022, 2, ltab025.	1.2	26
48	Regulatory T cells inhibit Fas ligand-induced innate and adaptive tumour immunity. <i>European Journal of Immunology</i> , 2007, 37, 758-767.	1.6	25
49	TCRâ€“induced alteration of primary MHC peptide anchor residue. <i>European Journal of Immunology</i> , 2019, 49, 1052-1066.	1.6	23
50	Enhanced antitumor immunity through sequential targeting of PI3K γ and LAG3. , 2020, 8, e000693.		22
51	Whole bloodâ€“based measurement of SARSâ€“CoVâ€“2â€“specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solidâ€“organ cancers. <i>Immunology</i> , 2022, 165, 250-259.	2.0	21
52	Clinical characteristics of hepatitis E in a â€“Nonâ€“Endemicâ€“ population. <i>Journal of Medical Virology</i> , 2010, 82, 1899-1902.	2.5	20
53	Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 64, 103937.	0.9	18
54	Expansion of hepatitis Câ€“specific CD4+CD25+ regulatory T cells after viral clearance: A mechanism to limit collateral damage?. <i>Journal of Allergy and Clinical Immunology</i> , 2008, 121, 1277-1284.e3.	1.5	17

#	ARTICLE	IF	CITATIONS
55	T cell subsets and colorectal cancer: Discerning the good from the bad. <i>Cellular Immunology</i> , 2012, 279, 21-24.	1.4	17
56	Immune Remodeling of the Extracellular Matrix Drives Loss of Cancer Stem Cells and Tumor Rejection. <i>Cancer Immunology Research</i> , 2020, 8, 1520-1531.	1.6	16
57	Eliminating roles for T-bet and IL-2 but revealing superior activation and proliferation as mechanisms underpinning dominance of regulatory T cells in tumors. <i>Oncotarget</i> , 2015, 6, 24649-24659.	0.8	16
58	A distinctive peptide binding motif for HLA-DRB1 * 0407, an HLA-DR4 subtype not associated with rheumatoid arthritis. <i>Immunogenetics</i> , 1997, 45, 229-232.	1.2	15
59	Rapid early innate control of hepatitis C virus during IFN α ± treatment compromises adaptive CD 4 + T α cell immunity. <i>European Journal of Immunology</i> , 2012, 42, 2383-2394.	1.6	15
60	Escalating Regulation of 5T4-Specific IFN- γ + CD4+ T Cells Distinguishes Colorectal Cancer Patients from Healthy Controls and Provides a Target for <i>In Vivo</i> Therapy. <i>Cancer Immunology Research</i> , 2013, 1, 416-425.	1.6	15
61	Tracking the kinetics of intrahepatic immune responses by repeated fine needle aspiration of the liver. <i>Journal of Immunological Methods</i> , 2015, 424, 131-135.	0.6	15
62	Persistent COVID-19 Infection in Wiskott-Aldrich Syndrome Cleared Following Therapeutic Vaccination: a Case Report. <i>Journal of Clinical Immunology</i> , 2022, 42, 32-35.	2.0	15
63	A case of persistent anemia and alcohol abuse. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2007, 4, 521-526.	1.7	14
64	Assessing the Prognostic Value of Preoperative Carcinoembryonic Antigen-Specific T-Cell Responses in Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	14
65	Chronic infections with viruses or parasites: breaking bad to make good. <i>Immunology</i> , 2017, 150, 389-396.	2.0	13
66	Molecular characterization of HLA class II binding to the LAG-3 T cell co-inhibitory receptor. <i>European Journal of Immunology</i> , 2021, 51, 331-341.	1.6	13
67	Enhanced Detection of Antigen-Specific CD4+ T Cells Using Altered Peptide Flanking Residue Peptide-MHC Class II Multimers. <i>Journal of Immunology</i> , 2015, 195, 5827-5836.	0.4	12
68	CD4+ T Cells Recognize Conserved Influenza A Epitopes through Shared Patterns of V-Gene Usage and Complementary Biochemical Features. <i>Cell Reports</i> , 2020, 32, 107885.	2.9	11
69	Human leukocyte antigen (HLA) class II peptide flanking residues tune the immunogenicity of a human tumor-derived epitope. <i>Journal of Biological Chemistry</i> , 2019, 294, 20246-20258.	1.6	10
70	The nature of the human T cell response to the cancer antigen 5T4 is determined by the balance of regulatory and inflammatory T cells of the same antigen-specificity: implications for vaccine design. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 247-256.	2.0	10
71	A distinct chemokine axis does not account for enrichment of Foxp3 ⁺ CD4 ⁺ T cells in carcinogen-induced fibrosarcomas. <i>Immunology</i> , 2015, 145, 94-104.	2.0	9
72	Molecular Rules Underpinning Enhanced Affinity Binding of Human T Cell Receptors Engineered for Immunotherapy. <i>Molecular Therapy - Oncolytics</i> , 2020, 18, 443-456.	2.0	9

#	ARTICLE	IF	CITATIONS
73	Primary breast tumours but not lung metastases induce protective anti-tumour immune responses after Treg-depletion. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2063-2073.	2.0	9
74	T-Cell Costimulation. <i>New England Journal of Medicine</i> , 2006, 355, 2594-2595.	13.9	8
75	Progression of carcinogen-induced fibrosarcomas is associated with the accumulation of naïve CD4+ T cells via blood vessels and lymphatics. <i>International Journal of Cancer</i> , 2014, 134, 2156-2167.	2.3	7
76	Elevated interleukin-6, interleukin-10 and neutrophil:lymphocyte ratio as identifiers of severe coronavirus disease 2019. <i>Immunology</i> , 2020, 160, 221-222.	2.0	5
77	Pouring petrol on the flames: Using oncolytic virotherapies to enhance tumour immunogenicity. <i>Immunology</i> , 2021, 163, 389-398.	2.0	5
78	High endothelial venules. <i>Oncolmmunology</i> , 2013, 2, e24272.	2.1	4
79	Avidity of influenza-specific memory CD8 ⁺ T cell populations decays over time compromising antiviral immunity. <i>European Journal of Immunology</i> , 2012, 42, 3235-3242.	1.6	3
80	Cancer Antigen Discovery Is Enabled by RNA Sequencing of Highly Purified Malignant and Nonmalignant Cells. <i>Clinical Cancer Research</i> , 2020, 26, 3360-3370.	3.2	3
81	Rapid innate control of antigen abrogates adaptive immunity. <i>Immunology</i> , 2013, 138, 293-297.	2.0	2
82	Prognostic significance of interleukin-17A-producing colorectal tumour antigen-specific T cells. <i>British Journal of Cancer</i> , 2021, 124, 1552-1555.	2.9	2
83	The Peptide Ligands Presented by MHC Class II Molecules. , 2016, , 209-214.		1
84	MVA-5T4 immunotherapy and low-dose cyclophosphamide for advanced colorectal cancer (TaCTiCC): An open-label, randomized phase I/II trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 154-154.	0.8	1
85	Latent viral infections in critically ill patients. <i>Critical Care</i> , 2009, 13, 410.	2.5	0
86	Setting the threshold for extrathymic differentiation of Foxp3 ⁺ Tregs: TGFβ ² -dependent and T cell autonomous. <i>European Journal of Immunology</i> , 2011, 41, 1218-1220.	1.6	0
87	Hunting for clues. <i>Oncolmmunology</i> , 2012, 1, 1163-1164.	2.1	0
88	Flow cytometry makes all the difference. <i>Journal of Hepatology</i> , 2013, 59, 909-910.	1.8	0